Molar-mass-dependent antibacterial activity of cationic dextran derivatives against resistant nosocomial pathogens.

The rise of various multidrug-resistant bacteria has created a need for new biocompatible and biodegradable antibacterial compounds. Cationic polysaccharides are promising candidates for this role. Therefore, cationic derivatives of commercial dextrans with molar masses of 11 kDa, 76 kDa, 411 kDa, and 1500-2500 kDa and various degrees of substitution (DSQ 0.34-0.52) were prepared and their antimicrobial properties against four gram-negative nosocomial bacteria were tested. As expected, a higher DSQ led to higher efficiency. The best antimicrobial properties were found for derivatives of 411 kDa, followed by 76 kDa and 1500-2000 kDa dextrans. This indicates that there is a certain optimum molar mass with the best antimicrobial properties. However, as molar mass increased, the biocompatibility of cationic dextran steadily decreased, with increased hemagglutination and toxicity being seen for human cells. The derivatives of 76 kDa dextran with higher DSQ (0.40-0.52) were the best antimicrobial agents suitable for further clinical testing.